树突状细胞联合细胞因子诱导杀伤细胞治疗晚期恶性肿瘤患者近期临床疗效观察_West China Medical Journal

Authors：

 沈杰 ¹ , 刘涛 ¹ , 张丹 ¹ , 兰大华 ¹ , 何凤 ¹ , 卢斌 ²

1. ;
2. ;

Corresponding author：

Keywords：

树突状细胞; 细胞因子诱导杀伤细胞; 晚期恶性肿瘤; 临床观察

DOI：

10.7507/1002-0179.20150026

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的观察研究树突状细胞（DC）联合细胞因子诱导杀伤细胞（CIK）协同治疗晚期恶性肿瘤患者的近期临床疗效。方法采集2013年1月－6月104例晚期恶性肿瘤患者外周血单个核细胞进行DC、CIK细胞培养，7～14 d后回输患者体内，观察治疗期不良反应症状及治疗前后免疫指标、生活质量变化情况，并评估治疗后病情缓解情况。结果治疗期低热5例，乏力3例，皮疹1例，无其他任何不良反应症状；治疗后患者外周血中CD3⁺、CD4⁺及自然杀伤细胞百分比上升，CD8⁺细胞百分比下降，生活质量指标及Karnofsky功能状态评分均有改善，差异有统计学意义（P＜0.05）；68例可测量病灶患者治疗后部分缓解18例，稳定42例，进展8例，客观缓解率为26.5%，疾病稳定率为88.2%。结论 DC/CIK细胞免疫治疗在杀灭肿瘤细胞的同时，可以修复患者免疫系统，改善患者生活质量，且安全性高，不良反应小，可成为继手术、放射治疗、化学治疗后晚期恶性肿瘤治疗的重要手段。

Citation： 沈杰, 刘涛, 张丹, 兰大华, 何凤, 卢斌. 树突状细胞联合细胞因子诱导杀伤细胞治疗晚期恶性肿瘤患者近期临床疗效观察. West China Medical Journal, 2015, 30(1): 97-99. doi: 10.7507/1002-0179.20150026 Copy

1.	He J, Gu D, Wu X, et al. Major causes of death among men and women in China[J]. N Engl J Med, 2005, 353(11):1124-1134.
2.	Hsu HS, Huang PI, Chang YL, et al. CucurbitacinⅠinhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung caner-derived CD133-positive cells[J]. Cancer, 2011, 117(13):2970-2985.
3.	鲍锋, 盛春华, 杨光. DC-CIK细胞治疗中晚期恶性肿瘤531例分析[J].中国免疫学杂志, 2011, 27(4):360-362.
4.	刘艳, 陈洪生, 刘明. DC、CIK细胞协同治疗晚期恶性肿瘤的临床观察[J].实用肿瘤学杂志, 2011, 25(1):6-9.
5.	詹俊, 孙小娟, 李楚强, 等. S100和CD83阳性树突状细胞与大肠肿瘤微环境的关系[J].世界华人消化杂志, 2009, 17(29):3061-3065.
6.	Nagaraj S, Ziske C, Schmidt-Wolf IG. Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral interleukin-2 gene transefer[J]. Genetic Vaccines and Ther, 2004, 2(1):12.
7.	Gao FG, Khammanivong V, Liu WJ, et al. Antigen-specific CD4(+) T-cell help is required to activate a memory CD8(+) T cell to a fully functional tumor killer cell[J]. Cancer Res, 2002, 62(22):6438-6441.
8.	Jiang J, Xu N, Wu C, et al. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells[J]. Anticancer Res, 2006, 26(3B):2237-2242.
9.	Li H, Yu JP, Cao S, et al. CD4+CD25+ regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) Cells of lung cancer patients[J]. J Clin Immunol, 2007, 27(3):317-326.
10.	Zoll B, Lefterova P, Ebert O, et al. Modulation of cell surface markers on NK-like T lymphocytes by using IL-2, IL-7 or IL-12 in vitro stimulation[J]. Cytokine, 2000, 12(9):1385-1390.
11.	Bryceson YT, Ljunggren HG. Tumor cell recognition by the NK cell activating receptor NKG2D[J]. Eur J Immunol, 2008, 38(11):2957-2961.
12.	匡志鹏, 梁安民. CIK细胞联合树突状细胞治疗恶性肿瘤的研究进展[J].现代肿瘤医学, 2006, 14(2):240-242.
13.	Märten A, Ziske C, Schöttker B, et al. Interactions between dendritic cells and cytokine-induced killer cells Lead to an activation of both populations[J]. J Immunother, 2001, 24(6):502-510.
14.	Wu J, Lu Y, Ding YB, et al. Promoter polymorphisms of IL2, IL4, and risk of gastric cancer in a high-risk Chinese population[J]. Mol Carcinog, 2009, 48(7):626-632.
15.	Horiuchi Y, Hanazawa A, Nakajima Y, et al. T-helper (Th)1/Th2 imbalance in the peripheral blood of dogs with malignant tumor[J]. Microbiol Immunol, 2007, 51(11):1135-1138.
16.	陈复兴, 刘军权, 张南征, 等.自身细胞因子诱导的杀伤细胞过继性免疫治疗恶性肿瘤的临床观察[J].癌症, 2002, 21(7):797-801.
17.	李成文. IL-2治疗的副作用[J].国外医学:输血及血液学分册, 1997, 20(3):169-172.

1. He J, Gu D, Wu X, et al. Major causes of death among men and women in China[J]. N Engl J Med, 2005, 353(11):1124-1134.
2. Hsu HS, Huang PI, Chang YL, et al. CucurbitacinⅠinhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung caner-derived CD133-positive cells[J]. Cancer, 2011, 117(13):2970-2985.
3. 鲍锋, 盛春华, 杨光. DC-CIK细胞治疗中晚期恶性肿瘤531例分析[J].中国免疫学杂志, 2011, 27(4):360-362.
4. 刘艳, 陈洪生, 刘明. DC、CIK细胞协同治疗晚期恶性肿瘤的临床观察[J].实用肿瘤学杂志, 2011, 25(1):6-9.
5. 詹俊, 孙小娟, 李楚强, 等. S100和CD83阳性树突状细胞与大肠肿瘤微环境的关系[J].世界华人消化杂志, 2009, 17(29):3061-3065.
6. Nagaraj S, Ziske C, Schmidt-Wolf IG. Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral interleukin-2 gene transefer[J]. Genetic Vaccines and Ther, 2004, 2(1):12.
7. Gao FG, Khammanivong V, Liu WJ, et al. Antigen-specific CD4(+) T-cell help is required to activate a memory CD8(+) T cell to a fully functional tumor killer cell[J]. Cancer Res, 2002, 62(22):6438-6441.
8. Jiang J, Xu N, Wu C, et al. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells[J]. Anticancer Res, 2006, 26(3B):2237-2242.
9. Li H, Yu JP, Cao S, et al. CD4+CD25+ regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) Cells of lung cancer patients[J]. J Clin Immunol, 2007, 27(3):317-326.
10. Zoll B, Lefterova P, Ebert O, et al. Modulation of cell surface markers on NK-like T lymphocytes by using IL-2, IL-7 or IL-12 in vitro stimulation[J]. Cytokine, 2000, 12(9):1385-1390.
11. Bryceson YT, Ljunggren HG. Tumor cell recognition by the NK cell activating receptor NKG2D[J]. Eur J Immunol, 2008, 38(11):2957-2961.
12. 匡志鹏, 梁安民. CIK细胞联合树突状细胞治疗恶性肿瘤的研究进展[J].现代肿瘤医学, 2006, 14(2):240-242.
13. Märten A, Ziske C, Schöttker B, et al. Interactions between dendritic cells and cytokine-induced killer cells Lead to an activation of both populations[J]. J Immunother, 2001, 24(6):502-510.
14. Wu J, Lu Y, Ding YB, et al. Promoter polymorphisms of IL2, IL4, and risk of gastric cancer in a high-risk Chinese population[J]. Mol Carcinog, 2009, 48(7):626-632.
15. Horiuchi Y, Hanazawa A, Nakajima Y, et al. T-helper (Th)1/Th2 imbalance in the peripheral blood of dogs with malignant tumor[J]. Microbiol Immunol, 2007, 51(11):1135-1138.
16. 陈复兴, 刘军权, 张南征, 等.自身细胞因子诱导的杀伤细胞过继性免疫治疗恶性肿瘤的临床观察[J].癌症, 2002, 21(7):797-801.
17. 李成文. IL-2治疗的副作用[J].国外医学:输血及血液学分册, 1997, 20(3):169-172.

Previous Article
Survey on the Antidepressant Use in In-patients with Depression

West China Medical Journal

树突状细胞联合细胞因子诱导杀伤细胞治疗晚期恶性肿瘤患者近期临床疗效观察

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content